This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Compelling Reasons to Hold Acadia Healthcare (ACHC) Stock Now
by Zacks Equity Research
Growing commercial, Medicare and Medicaid revenues will likely boost Acadia Healthcare's (ACHC) top line.
Here's Why Universal Health Services (UHS) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Acadia (ACHC) and Uber Health to Enhance Patient Access
by Zacks Equity Research
Acadia (ACHC) partners with Uber Health to ensure timely access to addiction treatment, breaking down transportation barriers for patients.
Humana's (HUM) Medicaid Business Teams Up With CPESN USA in Ohio
by Zacks Equity Research
Humana's (HUM) partnership with CPESN USA in Ohio aims to overcome barriers like limited access to healthcare services in rural and underserved communities.
Select Medical (SEM) Expands in Florida With UF Health JV
by Zacks Equity Research
Select Medical (SEM) inks a joint venture agreement with UF Health Jacksonville to open a 48-bed inpatient rehabilitation hospital in Florida.
UnitedHealth's (UNH) Optum to Buy Steward's Physician Group
by Zacks Equity Research
UnitedHealth (UNH) unit Optum's acquisition of Steward Health's physician group is expected to close in the second quarter of 2024.
Universal Health Services (UHS) Up 12.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Universal Health Services (UHS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You Looking for a Top Momentum Pick? Why Universal Health Services (UHS) is a Great Choice
by Zacks Equity Research
Does Universal Health Services (UHS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Should Value Investors Buy Universal Health Services (UHS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is Why Growth Investors Should Buy Universal Health Services (UHS) Now
by Zacks Equity Research
Universal Health Services (UHS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Profitable PEG-Based Value Stocks for Investors
by Urmimala Biswas
Here are five stocks that match our screening criteria - AEO, AL, DELL, UHS and PAGS.
Why Universal Health Services (UHS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Universal Health Services, Inc. (UHS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Universal Health Services (UHS) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
Universal Health Services (UHS) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Select Medical's (SEM) Concentra Submits Confidential IPO Filing
by Zacks Equity Research
The move from Select Medical's (SEM) Concentra highlights the recovery in the U.S. IPO market, especially for healthcare companies.
Evaluating Molina Healthcare's (MOH) Future View: Hold or Fold?
by Zacks Equity Research
Molina Healthcare's (MOH) top line is poised to gain from rising premium revenues and investment income.
Should You Add Universal Health (UHS) to Your Portfolio?
by Zacks Equity Research
Universal Health (UHS) remains well-poised for growth on growing patient volumes at its acute care and behavioral healthcare facilities, acquisitions and a commendable financial stand.
Why Elevance (ELV) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Elevance's (ELV) top line is poised to gain from rising product revenues, administrative fees and other revenues.
Elevance Health (ELV) Bolsters CarelonRx With Paragon Buyout
by Zacks Equity Research
The infusion services from Paragon Healthcare are expected to complement Elevance Health's (ELV) suite of pharmacy services.
An In-Depth Analysis of Encompass Health's (EHC) 2024 Outlook
by Zacks Equity Research
Growth in Medicare and Managed Care pricing, along with capacity additions of six de novos with 280 beds, will likely have an impact on Encompass Health's (EHC) 2024 bottom line.
Brookdale (BKD) February 2024 Weighted Average Occupancy Rises
by Zacks Equity Research
Brookdale (BKD) witnesses a continuous streak of 28 months of year-over-year improvements in the weighted average occupancy level.
The Joint (JYNT) Rises 30% as Q4 Earnings Beat on Higher Clinics
by Zacks Equity Research
The Joint (JYNT) expects 2024 system-wide sales to be within $530-$545 million.